During the last decade the frequency of therapy-related acute leukemia (t-leuk) and myelodysplastic syndrome It-MDS) has been increasingly observed. Over the past 15 years, we treated 56 patients with t-leuk who had received prior chemotherapy (39%). radiotherapy (1 1961, or both (45%). The drugs received included alkylating agents and topoisomerase II inhibitors. The primary tumors included hematological malignancies (49%) and solid tumors such as breast or ovarian cancer. The median age at diagnosis of the primary tumor was relatively young (43 years f 18). Twelve patients had more than one primary tumor and 31 patients had a family history of malignancy. Karyotypic abnormalities were found in 91% of the patients. Prognosis was uniformly poor, with an overall median survival of 10 months. Twelve of the 18 patients examined (67%) had a multidrug resistance phenotype. P53 genes of the leukemic cells, as well as the original tumors, were analyzed in 21 patients using HE DEVELOPMENT and widespread use of combina-T tion chemotherapy, as well as the combination of chemoradiotherapy has generally improved the outcome of many patients with cancer. However, impressive advances in the cure rate and survival have been accompanied by a distressing increase in the number of cases of therapy-related leukemia (t-leuk) and myelodysplastic syndromes (t-MDS).' Initial reports of AML following chemotherapy with alkylating agents were published in the 1970s,' and since then, the incidence of t-AML and t-MDS in patients treated for another malignancy has been estimated to range between 2% and 10% depending on a variety of factors including age, dose, duration, and the type of chemotherapy employed, as well as the use of combined chemoradiotherapy.' T-leuk represents approximately 10% to 15% of all AML.' When considering the number of patients exposed to chemotherapy and radiotherapy each year, it is critical to recognize the potential causes of therapy-related hone marrow (BM) damage to develop strategies to prevent it. Moreover, both t-leuk and t-MDS are much more resistant to treatment than the primary cancer and efforts to restore normal hematopoiesis have been largely unsuccessful.5
MDS) has been increasingly observed. Over the past 15 years, we treated 56 patients with t-leuk who had received prior chemotherapy (39%). radiotherapy (1 1961, or both (45%). The drugs received included alkylating agents and topoisomerase II inhibitors. The primary tumors included hematological malignancies (49%) and solid tumors such as breast or ovarian cancer. The median age at diagnosis of the primary tumor was relatively young (43 years f 18). Twelve patients had more than one primary tumor and 31 patients had a family history of malignancy. Karyotypic abnormalities were found in 91% of the patients. Prognosis was uniformly poor, with an overall median survival of 10 months. Twelve of the 18 patients examined (67%) had a multidrug resistance phenotype. P53 genes of the leukemic cells, as well as the original tumors, were analyzed in 21 patients using HE DEVELOPMENT and widespread use of combina-T tion chemotherapy, as well as the combination of chemoradiotherapy has generally improved the outcome of many patients with cancer. However, impressive advances in the cure rate and survival have been accompanied by a distressing increase in the number of cases of therapy-related leukemia (t-leuk) and myelodysplastic syndromes (t-MDS).' Initial reports of AML following chemotherapy with alkylating agents were published in the 1970s,' and since then, the incidence of t-AML and t-MDS in patients treated for another malignancy has been estimated to range between 2% and 10% depending on a variety of factors including age, dose, duration, and the type of chemotherapy employed, as well as the use of combined chemoradiotherapy.' T-leuk represents approximately 10% to 15% of all AML.' When considering the number of patients exposed to chemotherapy and radiotherapy each year, it is critical to recognize the potential causes of therapy-related hone marrow (BM) damage to develop strategies to prevent it. Moreover, both t-leuk and t-MDS are much more resistant to treatment than the primary cancer and efforts to restore normal hematopoiesis have been largely unsuccessful. 5 Two different types of t-leuk have emerged'; one type appears following therapy with alkylating agents, increases in frequency with age, and often presents with prior MDS, polymerase chain reaction (PCR) with single-stranded conformation polymorphism analysis followed by sequencing. P53 mutations were identified in 38% of these patients, a relatively high prevalence compared with other forms of MDS or de novo acute myeloid leukemia. Mutations were nongermline and restricted t o the leukemic cells. We identified different p53 mutations in the various primary tumors of individual patients. The presence of a mutator phenotype was assessed by PCR analysis of microsatellites in eight loci (one trinucleotide repeat sequence, four dinucleotide, and three mononuclear repeat sequences). Microsatellite instability in t w o t o seven loci were found in 15 of 16 (94%) of the patients. This instabifity i s compatible with a mutator phenotype, which predisposes the patients t o the development of malignancies including t-leuk. with poor response to chemotherapy. This type shows typical chromosomal changes including monosomy 7, (-7) monosomy 5 (-5), or loss of various portions of the long arms of these chromosomes (5q-and 7q-). The second class o f tleuk seems to be related to therapy with cytostatic drugs targeting DNA-topoisomerase 11, often presenting with overt acute leukemia and responds more favorably to chemotherapy. This type of t-leuk shows balanced chromosomal aherrations, primarily translocations involving chromosome bands l l q 2 3 and 21q22.7~"'
The common endpoint of treating leukemic cells with alkylating agents, topoisomerase I1 inhibitors, and radiation is DNA damage."." The tumor suppressor protein p53, which recognizes DNA breaks, directs cells with damaged DNA along the path of apoptosis. P53 also plays a central role as a key regulator in the cell cycle and has appropriately been termed "the guardian of the genome."13 The p53 gene, which consists of I 1 exons, 10 introns, and two promoters, is located on chromosome 17 p 13.1 .I4 Chromosome 17 has been cited as the third most frequently involved chromosome in secondary MDS and acute leukemia.','" Despite the fact that p53 mutations are infrequently encountered in de novo AML or MDS, we decided to study the role of this gene in patients with t-leuk, because of its role in cell cycle regulation following DNA damage.
MATERIALS AND METHODS

Patients.
We studied 56 patients with t-leuk and t-MDS diagnosed at Hadassah University Hospital from 1980 to 1994. The types of leukemia and MDS were diagnosed according to the FrenchAmerican-British (FAB) classification, using standard techniques including immunohistochemistry, immunophenotyping, cytogenetics, and molecular biology. For cytogenetic analysis, BM aspirates were processed according to the method of Michaeli et all5 using conditioned medium derived from the human bladder carcinoma cell line 5637. G-banding was performed according to Klinger Blood and BM samples from patients with tleuk and t-MDS were collected in EDTA. Fresh tumor tissue and blocks of paraffin-embedded tumor and BM biopsies were obtained from the same patients. Genomic DNA from phenol-chloroform extraction following proteinase K treatment.
DNA from paraffin-embedded tissue was prepared using thick sections from the block that were placed in a microfiige tube and deparaffinated with xylene. After drying. the pellets of tissue were resuspended in 48 p L of DNA lysis huffer (SO mmol/L Tris-HCI pH 7 5 , 0.1 moll1 NaCI. I nimol/L EDTA). A total of 2 p L of 10% sodium dodecyl sulfate (SDS) and 2 pL (20 pg/pL) of Proteinase K were added. and the samples were incubated overnight at 37°C. The DNA solution was purilied using Wizard miniprep DNA purification system (Promega. Madison. WI).
A total of 0. . Fony cycles of PCR were performed, with denaturation at 98°C for the first cycle and then 92°C for I minute. Annealing temperatures were S3OC to 58°C (for various primers) and extension was at 72°C for 30 seconds.'" Amplified PCR frngmcnts were analyzed hy SSCP clectrophoresis with 6% polyacrylamide. 10% glycerol gels (room temperature). which were run ovemight at 8 to IO W. Bands were detected after ovemight autoradiography of the gel.
Src/ircwcbi,q of SSCP ,firc,qi~ioir.s. Abnormal individual SSCP fragments were cut directly from the dried gel and eluted in distilled water. A 5-pL aliquot of supernatant containing the single stranded DNA was used for another round of PCR amplification with the corresponding primers. in a SO-pL reaction. PCR products were checked by gel electrophoresis and isolated from I % low melting agarose gels. The PCR reaction mix contained I x PCR buffer, 0.2 mmol/L dNTPs mix. 25 pmol of each primer. and I U of Taq polymerase. Forty cycles of PCR were performed as follows: denaturation at 94°C for 30 seconds. annealing at 53°C to S8.S"C. and extension at 70°C for 30 seconds.
Sequencing was performed on preheated (68°C for IO minutes) PCR products with DNA Sequencing Kit Version 2.0 (USB. Cleveland. OH) and analyzed on polyacrylamide gels with 7 mol/L urea. All samples were sequcnced with sense and antisense primers.
We examined the extrxted DNA for genetic alterations at eight separate microsatellites. localized to the following chromosomes: 17p (p53 gene. a dinucleotide repeat)."' 14p (D14S426. a dinucleotide repeat retrieved from the GDB data hase: F primer: CCCCAAATATCACTCCAAAT. R primer: GAGTTGGCAACCACTTCTGT). I3p (Rh gene. a dinucleotide repeat).'" 1Sq (GABRB3, a dinucleotide repeat)." and 19p (DMI gene. a trinucleotide repeat)." BAT 25 and BAT 40 are randomly chosen microsatellite markers consisting of an (A)n repeat.'' and a (T)n repeat in the eighth intron of the cystic fihrosis transmemhrane conductance regulator (CFTR gene) on chromosome 7q." Amplified fragments were analyzed on 12% polyacrylamide gels with visualization of hands using ethidium bromide (pS3 microsatellite). or by P" radiolahled PCR (RB gene). The D14S426. the GABRB3. the myotonic dystrophy (DMI) genes. and the mononucleotide repeats were visualized using silver staining technique as described. '5 The protocols for the analysis of these loci were as previously described. '''.'' RESULTS ?'dents. A markedly increased number of cases of tleuk were observed during the past 5 years; 37 patients were diagnosed between 1990 and 1994, compared with only 19 patients seen between 1980 and 1989 (Fig I) . Thirty-eight patients were women and 18 were men. The primary tumors included hematological malignancies (49%) and solid tumors. among which breast and ovarian cancer were the most common. accounting for the obvious female predominance ( Table I) .
The median ape at diagnosis of the primary tumor was generally relatively young. For example, the median age at diagnosis of breast carcinoma and ovarian carcinoma was 43 and 48 years, respectively, whereas in the general Israeli population. the median ape at diagnosis is 60 years for breast and 63 for ovarian carcinoma. Twelve patients had more than one primary tumor and three had more than two. More than half of the cases (31 patients) had a family history of malignant disease. Primary tumors, were treated with chemo- therapy (52%), radiotherapy (7%). or both modalities (41 %). Drugs included alkylating agents (60%) and topoisomerase I1 inhibitors, either alone (15%) or in combination with alkylating agents (25%).
The time interval between completion of the primary therapy and the diagnosis of the t-leuk or t-MDS was relatively short. Half of the patients developed t-leuk or t-MDS within 2 years of therapy, while the frequency decreased markedly approaching the fifth year posttreatment (Fig 2) . The types of tleuk included AML (54%), MDS in transformation (38%), and ALL (8%). Of the 46 patients analyzed, 42 had an abnormal karyotype (91%) (Fig 3 and Table 2 ). and in 21 cases (469) the abnormality was of chromosomes 5 and/or 7.
Ten patients underwent allogeneic BM transplantation and one autologous transplant. All the other patients were treated with either single agent or combination chemotherapy. The median survival was 26 months for the transplanted patients. compared with 8 months in the remaining cases.
Eighteen patients were assessed for the presence of rhodamine 123 efflux, a standard assay for activity of the MDRI protein (Fig 4) . Twelve patients (67%) were positive for rhodamine efflux. Of the six who were negative, all but one had balanced cytogenetic aberrations. Among them, three had acute promyelocytic leukemia, with a typical t(15: 17) translocation as the sole chromosomal abnormality. and two had a t(9; 11) translocation following treatment with etoposide. All the MDRl positive patients, except for one, had deletions or absence of chromosomes 5 or 7, or trisomy 8.
We analyzed 68 samples from 21 patients and found p53 mutations in the t-leuk cells in eight cases (38%). The mutations were nongermline and restricted to the t-leuk cells. The mutations were not identified in the patients' normal tissues, ie, fibroblasts or normal BM cells (collected in complete remission). We analyzed the DNA of the primary tumors in these patients and found different p53 mutations in each of their primary tumors. Only one of the mutations was a nonsense mutation, while all the others were missense mutations (Fig 5A and B) .
Microsatellite insrnhilit?,. The number of repeated sequences in the DNA obtained from the t-leuk or t-MDS cells, as well as the primary tumors, were compared with normal tissue obtained from the same patient. Table 3 details the results for each patient. We found evidence for microsatellite instability at the p53 locus in all eight patients who had a p53 mutation and in only one of the 13 patients without a p53 mutation. Sixteen of these patients were analyzed for microsatellite instability at other loci. Fifteen of these (94%) had microsatellite instability at two to seven loci (Fig 6a and b, Table 3 ). TWO patients had instability in two loci, four patients in three loci,
Millridrug resisrnnce nnalysis.
p53 mrrrtrrior7s.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From studies found that alkylating agents, drugs that bind to topo-MDS during the last 5 years compared with the prior decade. isomerase 11, antimetabolites, as well as energy-rich radiaWe also found a short latent period between the treatment tion. induced p53 overexpression. The accumulation of wildof the primary tumor and the development and diagnosis of type p53 arrests cell cycle progression until initial DNA t-leuk or t-MDS. Dose intensification of cytotoxic drugs in damage is repaired, but if the repair fails, p53 may then recent years and the increased usage of etoposide may conproceed to trigger apoptosis.
tribute to these observations. We studied 56 patients with t-leuk or t-MDS and found
Because the patients studied were selected according to a significant increase in the number of cases of t-leuk or tthe diagnosis of t-leuk or t-MDS, they did not comprise a For personal use only. on September 24, 2017. by guest www.bloodjournal.org From homogenous group with regard to the primary type of tumor tients have a predisposition to acquire mutations, known as or the treatment given. This was particularly striking in the cases diagnosed during the last 5 years (Fig 2) . The most prominent features of this group were: young age at the time of diagnosis of the primary malignancy, more than one primary tumor, and a family history of cancer. Each of these characteristics suggests a genetic susceptibility to cancer. Most patients received heavy treatment with multiple agents for their primary malignancies, and in most cases, t-leuk was characterized by cytogenetic aberrations (including del (17p) or -17 in 13% of the patients), MDRI overexpression and a poor therapeutic outcome.
The fact that p53 has been shown to accumulate in cultured cells treated with chemoradiotherapy prompted us to study the P53 gene in these patients. We found a high frequency of mutations in this gene (38%). This is in contrast to patients with primary AML and MDS in whom the frequency of p53 mutations was found to be low, 13 of 204 AML patients (6%)2x-30 and 12 of 258 MDS patients nature of t-leuk and t-MDS in our patients, including the high frequency of p53 lesions found, all the mutations encountered were restricted to the leukemic cells and were nongermline in nature. Furthermore, different mutations were found in a variety of primary tumors in individual patients. Taken together, these data suggest that these pa-(5yo).3I." Despite the suggestive evidence for the familial a mutator phenotype.
The concept that oncogenesis involves a mutator phenotype has recently been considered by several investigators.33 The first set of genes to be studied were those that participate in mismatch repair and are responsible for correcting replication errors. Five human genes involved in DNA mismatch repair, MSH2, MLH1, PMS l , PMS2, and GTBP have recently been cloned and characterized.".'" Germline mutations in these genes cause heritable susceptibility to colorectal and related cancers." In our series of patients, mismatch repair genes could not be studied directly because of insufficient amounts of DNA and RNA.
Therefore, we looked for microsatellite instability as an indicator of a mutator phenotype. Each microsatellite contains multiple repetitive nucleotide sequences that are relatively constant in normal cells. Variation in the repeat number and the microsatellite's length, due to slippage during DNA replication, may be caused by a variety of factors. Microsatellite variations reflect genomic instability and have been observed in certain tumors. In some of these cancers, they occur concomitantly with mutations in mismatch repair genes." The latter appear to be an early event in the development of cancer, as they have been demonstrated in diploid colon cancer cells.'9.3x It was suggested that the mutations in "stability" genes generate a series of secondary mutations For personal use only. on September 24, 2017. by guest www.bloodjournal.org From throughout the genome. Some of these involve oncogenes that alter the regulatow mechanisms of the cell, which may lead to the development of tumors. It is, therefore, significant that we found microsatellite instability in up to 94% of the patients with t-leuk or t-MDS, suggesting a mutator phenotype in these patients. The fact that we found microsatellite instability at the p53 locus in all the cases who had a p53 mutation, but in only one of the patients who lacked a p53 mutation, is an intriguing finding. This raises the question of the biological role of microsatellite instability of a given gene on the generation of mutations in that gene.
Our suggested hypothesis for the development of t-leuk or t-MDS is as follows: patients who have a mutator phenotype because of germline inherited mutations in a stability gene, are likely to develop cancer at an early age. The treatment given for the primary malignancy appears to accelerate DNA instability in many additional cancer-associated genes (eg, oncogenes and tumor suppressor genes), contributing to the development of secondary malignancies. An altemative hypothesis is that the treatment given for the primary disease causes acquired mutations in DNA stability genes. Thus, identification of the genes involved in the mutator phenotype would allow us to distinguish between these two possibilities. The ability to identify patients who have preexisting abnormalities of these genes could enable the development of strategies to prevent DNA damage to the BM. These could include cryopreservation of uninvolved autologous marrow before the administration of chemotherapy in specific cases. As a first step in this direction, we are currently studying the mismatch repair genes in the increasing number of newly diagnosed patients with t-leuk or t-MDS.
